Share This Article:

The Role of Hyperinsulenemia as a Risk Factor for Pancreatic Cancer

Abstract Full-Text HTML Download Download as PDF (Size:263KB) PP. 1459-1465
DOI: 10.4236/jct.2013.410175    3,902 Downloads   4,939 Views  


Background: Pancreatic cancer is associated with a very severe prognosis and identification of risk factors is essential. Diabetes and obesity are both established risk factors, and they both cause hyperinsulenemia. With this review we wished to appraise the evidence of a role of high insulin levels in causing pancreatic cancer. Methods: We searched PubMed, Embase, Cochrane Library and Medline, and all evidence on potential pathophysiology of hyperinsulenemia and pancreatic cancer was included. Metaand pooled-analysis on epidemiological evidence are reported, and individual studies were as appropriate for specific topics (role of therapies, central adiposity and role of physical exercise). Conclusion: Hyperinsulenemia, and possibly hyperestrogenism secondary to a metabolic syndrome, are important elements in the pathogenesis of pancreatic cancer. Modification of certain life-style factors (exercise and weight loss) appears to modify the risk of pancreatic malignancy.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

G. Preziosi, J. Oben and G. Fusai, "The Role of Hyperinsulenemia as a Risk Factor for Pancreatic Cancer," Journal of Cancer Therapy, Vol. 4 No. 10, 2013, pp. 1459-1465. doi: 10.4236/jct.2013.410175.


[1] UK CR.
[2] J. T. McPhee, J. S. Hill, G. F. Whalen, M. Zayaruzny, D. E. Litwin, M. E. Sullivan, et al., “Perioperative Mortality for Pancreatectomy: A National Perspective,” Annals of Surgery, Vol. 246, No. 2, 2007, pp. 246-253.
[3] B. Gudjonsson, “Cancer of the Pancreas. 50 Years of Surgery,” Cancer, Vol. 60, No. 9, 1987, pp. 2284-2303.<2284::AID-CNCR2820600930>3.0. CO;2-V
[4] J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers and D. M. Parkin, “Estimates of Worldwide Burden of Cancer in 2008: Globocan 2008,” International Journal of Cancer, Vol. 127, No. 12, 2010, pp. 2893-2917.
[5] S. Iodice, S. Gandini, P. Maisonneuve and A. B. Lowenfels, “Tobacco and the Risk of Pancreatic Cancer: A Review and Meta-Analysis,” Langenbeck’s Archives of Surgery, Vol. 393, No., 2008, pp. 535-545.
[6] D. T. Silverman, J. A. Dunn, R. N. Hoover, M. Schiffman, K. D. Lillemoe, J. B. Schoenberg, et al., “Cigarette Smoking and Pancreas Cancer: A Case-Control Study Based on Direct Interviews,” Journal of the National Cancer Institute, Vol. 86, No. 20, 1994, pp. 1510-1516. 1093/jnci/86.20.1510
[7] J. T. Magruder, D. Elahi and D. K. Andersen, “Diabetes and Pancreatic Cancer: Chicken or Egg?” Pancreas, Vol. 40, No. 3, 2011, pp. 339-351.
[8] J. Everhart and D. Wright, “Diabetes Mellitus as a Risk Factor for Pancreatic Cancer. A Meta-Analysis,” JAMA, Vol. 273, No. 20, 1995, pp. 1605-1609.
[9] R. Huxley, A. Ansary-Moghaddam, A. Berrington de Gonzalez, F. Barzi, M. Woodward, “Type-II Diabetes and Pancreatic Cancer: A Meta-Analysis of 36 Studies,” British Journal of Cancer, Vol. 92, 2005, pp. 2076-2083.
[10] Q. Ben, M. Xu, X. Ning, J. Liu, S. Hong, W. Huang, et al., “Diabetes Mellitus and Risk of Pancreatic Cancer: A Meta-Analysis of Cohort Studies,” European Journal of Cancer, Vol. 47, No. 13, 2011, pp. 1928-1937.
[11] AICR, World Cancer Research Fund/American Institute for Cancer Research, “Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective,” 2007.
[12] B. B. Kahn and J. S. Flier, “Obesity and Insulin Resistance,” Journal of Clinical Investigation, Vol. 106, No. 4, 2000, pp. 473-481.
[13] V. J. Carey, E. E. Walters, G. A. Colditz, C. G. Solomon, W. C. Willett, B. A. Rosner, et al., “Body Fat Distribution and Risk of Non-Insulin-Dependent Diabetes Mellitus in Women. The Nurses’ Health Study,” American Journal of Epidemiology, Vol. 145, No. 7, 1997, pp. 614-619.
[14] H. Wahrenberg, K. Hertel, B. M. Leijonhufvud, L. G. Persson, E. Toft and P. Arner, “Use of Waist Circumference to Predict Insulin Resistance: Retrospective Study,” BMJ, Vol. 330, 2005, pp. 1363-1364.
[15] P. Bjorntorp, “Metabolic Implications of Body Fat Distribution,” Diabetes Care, Vol. 14, No. 12, 1991, pp. 1132-1143.
[16] M. W. Rajala and P. E. Scherer, “Minireview: The Adipocyte—At the Crossroads of Energy Homeostasis, Inflammation, and Atherosclerosis,” Endocrinology, Vol. 144, No. 9, 2003, pp. 3765-3773.
[17] A. G. Renehan, M. Tyson, M. Egger, R. F. Heller and M. Zwahlen, “Body-Mass Index and Incidence of Cancer: A Systematic Review and Meta-Analysis of Prospective Observational Studies,” Lancet, Vol. 371, No. 9612, 2008, pp. 569-578.
[18] G. M. Reaven, “Banting Lecture 1988. Role of Insulin Resistance in Human Disease,” Diabetes, Vol. 37, No. 12, 1988, pp. 1595-1607.
[19] B. L. Wajchenberg, “Subcutaneous and Visceral Adipose Tissue: Their Relation to the Metabolic Syndrome,” Endocrine Reviews, Vol. 21, No. 6, 2000, pp. 697-738. 1210/er.21.6.697
[20] R. Z. Stolzenberg-Solomon, S. Weinstein, M. Pollak, Y. Tao, P. R. Taylor, J. Virtamo, et al., “Prediagnostic Adiponectin Concentrations and Pancreatic Cancer Risk in Male Smokers,” American Journal of Epidemiology, Vol. 168, No. 9, 2008, pp. 1047-1055.
[21] S. M. Shafie and R. Hilf, “Insulin Receptor Levels and Magnitude of Insulin-Induced Responses in 7,12-Dimethylbenz(a)Anthracene-Induced Mammary Tumors in Rats,” Cancer Research, Vol. 41, 1981, pp. 826-829.
[22] J. A. Williams and I. D. Goldfine, “The Insulin-Pancreatic Acinar Axis,” Diabetes, Vol. 34, No. 10, 1985, pp. 980-986.
[23] J. R. Henderson, P. M. Daniel and P. A. Fraser, “The Pancreas as a Single Organ: The Influence of the Endocrine upon the Exocrine Part of the Gland,” Gut, Vol. 22, 1981, pp. 158-167.
[24] W. E. Fisher, L. G. Boros and W. J. Schirmer, “Insulin Promotes Pancreatic Cancer: Evidence for Endocrine Influence on Exocrine Pancreatic Tumors,” Journal of Surgical Research, Vol. 63, No. 1, 1996, pp. 310-313.
[25] F. Wang, J. Larsson, T. E. Adrian, T. Gasslander and J. Permert, “In Vitro Influences between Pancreatic Adenocarcinoma Cells and Pancreatic Islets,” Journal of Surgical Research, Vol. 79, No. 1, 1998, pp. 13-19.
[26] M. B. Schneider, H. Matsuzaki, J. Haorah, A. Ulrich, J. Standop, X. Z. Ding, et al., “Prevention of Pancreatic Cancer Induction in Hamsters by Metformin,” Gastroenterology, Vol. 120, No. 5, 2001, pp. 1263-1270.
[27] J. Liu, K. Kazakoff, P. M. Pour and T. E. Adrian, “The Intracellular Mechanism of Insulin Resistance in the Hamster Pancreatic Ductal Adenocarcinoma Model,” Pancreas, Vol. 17, No. 4, 1998, pp. 359-366.
[28] K. Kazakoff, T. Cardesa, J. Liu, T. E. Adrian, D. Bagchi, M. Bagchi, et al., “Effects of Voluntary Physical Exercise on High-Fat Diet-Promoted Pancreatic Carcinogenesis in the Hamster Model,” Nutrition and Cancer, Vol. 26, No. 3, 1996, pp. 265-279.
[29] R. H. Bell Jr., P. J. McCullough and P. M. Pour, “Influence of Diabetes on Susceptibility to Experimental Pancreatic Cancer,” The American Journal of Surgery, Vol. 155, No. 1, 1988, pp. 159-164.
[30] P. M. Pour, K. Kazakoff and K. Carlson, “Inhibition of Streptozotocin-Induced Islet Cell Tumors and N-Nitrosobis (2-oxopropyl)Amine-Induced Pancreatic Exocrine Tumors in Syrian Hamsters by Exogenous Insulin,” Cancer Research, Vol. 50, 1990, pp. 1634-1639.
[31] P. M. Pour and K. Stepan, “Modification of Pancreatic Carcinogenesis in the Hamster Model. VIII. Inhibitory Effect of Exogenous Insulin,” Journal of the National Cancer Institute, Vol. 72, 1984, pp. 1205-1208.
[32] M. A. Lawlor and D. R. Alessi, “PKB/Akt: A Key Mediator of Cell Proliferation, Survival and Insulin Responses?” Journal of Cell Science, Vol. 114, No. 16, 2001, pp. 2903-2910.
[33] M. Prisco, G. Romano, F. Peruzzi, B. Valentinis and R. Baserga, “Insulin and IGF-I Receptors Signaling in Protection from Apoptosis,” Hormone and Metabolic Research, Vol. 31, No. 2-3, 1999, pp. 80-89.
[34] E. Ohmura, M. Okada, N. Onoda, Y. Kamiya, H. Murakami, T. Tsushima, et al., “Insulin-Like Growth Factor I and Transforming Growth Factor Alpha as Autocrine Growth Factors in Human Pancreatic Cancer Cell Growth,” Cancer Research, Vol. 50, 1990, pp. 103-107.
[35] A. E. Butler, R. Galasso, A. Matveyenko, R. A. Rizza, S. Dry, P. C. Butler, “Pancreatic Duct Replication is Increased with Obesity and Type 2 Diabetes in Humans,” Diabetologia, Vol. 53, No. 1, 2010, pp. 21-26.
[36] X. Z. Ding, D. M. Fehsenfeld, L. O. Murphy, J. Permert and T. E. Adrian, “Physiological Concentrations of Insulin Augment Pancreatic Cancer Cell Proliferation and Glucose Utilization by Activating MAP Kinase, PI3 Kinase and Enhancing GLUT-1 Expression,” Pancreas, Vol. 21, No. 3, 2000, pp. 310-320.
[37] S. M. Gapstur, P. H. Gann, W. Lowe, K. Liu, L. Colangelo and A. Dyer, “Abnormal Glucose Metabolism and pancreatic Cancer Mortality,” JAMA, Vol. 283, No. 19, 2000, pp. 2552-2558.
[38] S. H. Jee, H. Ohrr, J. W. Sull, J. E. Yun, M. Ji and J. M. Samet, “Fasting Serum Glucose Level and Cancer Risk in Korean Men and Women,” JAMA, Vol. 293, No. 2, 2005, pp. 194-202.
[39] R. Z. Stolzenberg-Solomon, B. I. Graubard, S. Chari, P. Limburg, P. R. Taylor, J. Virtamo and D. Albanes, “Insulin, Glucose, Insulin Resistance, and Pancreatic Cancer in Male Smokers,” JAMA, Vol. 294, No. 22, 2005, pp. 2872-2878.
[40] L. Bonelli, H. Aste, P. Bovo, G. Cavallini, M. Felder, R. Gusmaroli, E. Morandini, P. Ravelli, R. Briglia, L. Lombardo, A. De Micheli and V. Pugliese, “Exocrine Pancreatic Cancer, Cigarette Smoking, and Diabetes Mellitus: A Case-Control Study in Northern Italy,” Pancreas, Vol. 27, No. 2, 2003, pp. 143-149.
[41] P. Maisonneuve, A. B. Lowenfels, H. B. Bueno-de-Mesquita, P. Ghadirian, P. A. Baghurst, W. A. Zatonski, A. B. Miller, E. J. Duell, P. Boffetta and B. Peter, “Past Medical History and Pancreatic Cancer Risk: Results from a Multicenter Case-Control Study,” Annals of Epidemiology, Vol. 20, No. 2, 2010, pp. 92-98.
[42] M. Pollak, “Insulin and Insulin-Like Growth Factor Signalling in Neoplasia,” Nature Reviews Cancer, Vol. 8, No. 12, 2008, pp. 915-928.
[43] E. Rozengurt, J. Sinnett-Smith and K. Kisfalvi, “Crosstalk between Insulin/Insulin-Like Growth Factor-1 Receptors and G Protein-Coupled Receptor Signaling Systems: A Novel Target for the Antidiabetic Drug Metformin in Pancreatic Cancer,” Clinical Cancer Research, Vol. 16, No. 9, 2010, pp. 2505-2511.
[44] R. J. Shaw, K. A. Lamia, D. Vasquez, S. H. Koo, N. Bardeesy, R. A. Depinho, M. Montminy and L. C. Cantley, “The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin,” Science, Vol. 310, No. 5754, 2005, pp. 1642-1646. 1120781
[45] M. Zakikhani, R. Dowling, I. G. Fantus, N. Sonenberg and M. Pollak, “Metformin Is an AMP Kinase-Dependent Growth Inhibitor for Breast Cancer Cells,” Cancer Research, Vol. 66, No. 21, 2006, pp. 10269-10273.
[46] K. Kisfalvi, G. Eibl, J. Sinnett-Smith and E. Rozengurt, “Metformin Disrupts Crosstalk between G Protein-Coupled Receptor and Insulin Receptor Signaling Systems and Inhibits Pancreatic Cancer Growth,” Cancer Research, Vol. 69, No. , 2009, pp. 6539-6545. CAN-09-0418
[47] R. J. Shaw, N. Bardeesy, B. D. Manning, L. Lopez, M. Kosmatka, R. A. DePinho and L. C. Cantley, “The LKB1 Tumor Suppressor Negatively Regulates mTOR Signaling,” Cancer Cell, Vol. 6 , No. 1, 2004, pp. 91-99.
[48] D. R. Alessi, K. Sakamoto and J. R. Bayascas. “LKB1-Dependent Signaling Pathways,” Annual Review of Biochemistry, Vol. 75, 2006, pp. 137-163. 142702.
[49] A. Tchernof and J. P. Despres, “Sex Steroid Hormones, Sex Hormone-Binding Globulin, and Obesity in Men and Women,” Hormone and Metabolic Research, Vol. 32, No. 11-12, 2000, pp. 526-536.
[50] A. B. Miller, T. H. Barclay, N. W. Choi, M. G. Grace, C. Wall, M. Plante, G. R. Howe, B. Cinader and F. G. Davis, “A Study of Cancer, Parity and Age at First Pregnancy,” Journal of Chronic Diseases, Vol. 33, No. 10, 1980, pp. 595-605.
[51] H. B. Bueno de Mesquita, P. Maisonneuve, C. J. Moerman and A. M. Walker, “Anthropometric and Reproductive Variables and Exocrine Carcinoma of the Pancreas: A Population-Based Case-Control Study in The Netherlands,” International Journal of Cancer, Vol. 52, No. 1, 1992, pp. 24-29.
[52] N. Abate, “Insulin Resistance and Obesity. The Role of Fat Distribution Pattern,” Diabetes Care, Vol. 19, No. 3, 1996, pp. 292-294.
[53] A. V. Patel, C. Rodriguez, L. Bernstein, A. Chao, M. J. Thun and E. E. Calle, “Obesity, Recreational Physical Activity, and Risk of Pancreatic Cancer in a Large U.S. Cohort,” Cancer Epidemiology, Biomarkers & Prevention, Vol. 14, No. 2, 2005, pp. 459-466. EPI-04-0583
[54] S. C. Larsson, J. Permert, N. Hakansson, I. Naslund, L. Bergkvist and A. Wolk, “Overall Obesity, Abdominal Adiposity, Diabetes and Cigarette Smoking in Relation to the Risk of Pancreatic Cancer in Two Swedish Population-Based Cohorts,” British Journal of Cancer, Vol. 93, No. 11, 2005, pp. 1310-1315.
[55] A. Berrington de Gonzalez, E. A. Spencer, H. B. Bueno-de-Mesquita, A. Roddam, R. Stolzenberg-Solomon, J. Halkjaer, et al., “Anthropometry, Physical Activity, and the Risk of Pancreatic Cancer in the European Prospective Investigation into Cancer and Nutrition,” Cancer Epidemiology, Biomarkers & Prevention, Vol. 15, No. 5, 2006, pp. 879-885.
[56] A. Ansary-Moghaddam, R. Huxley, F. Barzi, C. Lawes, T. Ohkubo, X. H. Fang, S. H. Jee, M. Woodward and Asia Pacific Cohort Studies Collaboration, “The Effect of Modifiable Risk Factors on Pancreatic Cancer Mortality in Populations of the Asia-Pacific Region,” Cancer Epidemiology, Biomarkers & Prevention, Vol. 15, No. 12, 2006, pp. 2435-2440.
[57] R. Z. Stolzenberg-Solomon, K. Adams, M. Leitzmann, C. Schairer, D. S. Michaud, A. Hollenbeck, A. Schatzkin and D. T. Silverman, “Adiposity, Physical Activity, and Pancreatic Cancer in the National Institutes of Health-AARP Diet and Health Cohort,” American Journal of Epidemiology, Vol. 167, No. 5, 2008, pp. 586-597.
[58] J. Luo, K. L. Margolis, H. O. Adami, A. LaCroix and W. Ye, “Obesity and Risk of Pancreatic Cancer among Postmenopausal Women: The Women’s Health Initiative (United States),” British Journal of Cancer, Vol. 99, No. 3, 2008, pp. 527-531.
[59] Y. Oshida, K. Yamanouchi, S. Hayamizu and Y. Sato, “Long-Term Mild Jogging Increases Insulin Action Despite no Influence on Body Mass Index or VO2 Max,” Journal of Applied Physiology, Vol. 66, No. 5, 1989, pp. 2206-2210.
[60] D. E. Kelley and B. H. Goodpaster. “Effects of Physical Activity on Insulin Action and Glucose Tolerance in Obesity,” Medicine & Science in Sports & Exercise, Vol. 31, No. 11, 1999, pp. S619-S623.
[61] D. S. Michaud, E. Giovannucci, W. C. Willett, G. A. Colditz, M. J. Stampfer and C. S. Fuchs, “Physical Activity, Obesity, Height, and the Risk of Pancreatic Cancer,” JAMA, Vol. 286, No. 8, 2001, pp. 921-929.
[62] B. Isaksson, F. Jonsson, N. L. Pedersen, J. Larsson, M. Feychting and J. Permert “Lifestyle Factors and Pancreatic Cancer Risk: A Cohort Study from the Swedish Twin Registry,” International Journal of Cancer, Vol. 98, No. 3, 2002, pp. 480-482.
[63] A. J. Hanley, K. C. Johnson, P. J. Villeneuve and Y. Mao, “Physical Activity, Anthropometric Factors and Risk of Pancreatic Cancer: Results from the Canadian Enhanced Cancer Surveillance System,” International Journal of Cancer, Vol. 94, No. 1, 2001, pp. 140-147.
[64] D. Aune, D. C. Greenwood, D. S. Chan, R. Vieira, A. R. Vieira, D. A. Navarro Rosenblatt, J. E. Cade, V. J. Burley and T. Norat, “Body Mass Index, Abdominal Fatness and Pancreatic Cancer Risk: A Systematic Review and Non-Linear Dose-Response Meta-Analysis Of Prospective Studies,” Annals of Oncology, Vol. 23, No. 4, 2011, pp. 843-852.
[65] J. M. Genkinger, D. Spiegelman, K. E. Anderson, L. Bernstein, P. A. van den Brandt, E. E. Calle, et al., “A Pooled Analysis of 14 Cohort Studies of Anthropometric Factors and Pancreatic Cancer Risk,” International Journal of Cancer, Vol. 129, No. 7, 2011, pp. 1708-1717. 1002/ijc.25794
[66] A. A. Arslan, K. J. Helzlsouer, C. Kooperberg, X. O. Shu, E. Steplowski, H. B. Bueno-de-Mesquita, et al., “Anthropometric Measures, Body Mass Index, and Pancreatic Cancer: A Pooled Analysis from the Pancreatic Cancer Cohort Consortium (PanScan),” JAMA, Vol. 170, No. 9, 2010, pp. 791-802.
[67] N. V. Christou, M. Lieberman, F. Sampalis and J. S. Sampalis, “Bariatric Surgery Reduces Cancer Risk in Morbidly Obese Patients,” Surgery for Obesity and Related Diseases, Vol. 4, No. 6, 2008, pp. 691-695.
[68] T. D. Adams, A. M. Stroup, R. E. Gress, K. F. Adams, E. E. Calle, S. C. Smith, R. C. Halverson, S. C. Simper, P. N. Hopkins and S. C. Hunt, “Cancer Incidence and Mortality after Gastric Bypass Surgery,” Obesity, Vol. 17, No. 4, 2009, pp. 796-802.

comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.